Venus Remedies [VENUSREM] vs Wanbury [WANBURY] Detailed Stock Comparison
Venus Remedies
NSE
Loading...
Wanbury
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Venus Remedies wins in 11 metrics, Wanbury wins in 7 metrics, with 1 ties. Venus Remedies appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Venus Remedies | Wanbury | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 11.44 | 22.12 | Venus Remedies |
| Price-to-Book Ratio | 1.09 | 15.42 | Venus Remedies |
| Debt-to-Equity Ratio | 0.30 | 298.48 | Venus Remedies |
| PEG Ratio | 0.02 | 0.02 | Tie |
| EV/EBITDA | 6.91 | 11.94 | Venus Remedies |
| Profit Margin (TTM) | 8.00% | 6.81% | Venus Remedies |
| Operating Margin (TTM) | 2.97% | 12.75% | Wanbury |
| EBITDA Margin (TTM) | 2.97% | 12.75% | Wanbury |
| Return on Equity | 8.08% | 51.51% | Wanbury |
| Return on Assets (TTM) | 6.33% | 7.38% | Wanbury |
| Free Cash Flow (TTM) | $683.65M | $-229.26M | Venus Remedies |
| 1-Year Return | 31.25% | 5.29% | Venus Remedies |
| Price-to-Sales Ratio (TTM) | 0.92 | 1.45 | Venus Remedies |
| Enterprise Value | $4.59B | $10.77B | Wanbury |
| EV/Revenue Ratio | 0.68 | 1.71 | Venus Remedies |
| Gross Profit Margin (TTM) | 43.78% | 53.83% | Wanbury |
| Revenue per Share (TTM) | $501 | $192 | Venus Remedies |
| Earnings per Share (Diluted) | $40.15 | $12.61 | Venus Remedies |
| Beta (Stock Volatility) | 0.40 | 0.15 | Wanbury |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Venus Remedies vs Wanbury Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Venus Remedies | -0.60% | 2.09% | -3.28% | 4.94% | 55.76% | 45.92% |
| Wanbury | -2.85% | -0.92% | 7.37% | -6.10% | 32.92% | -7.48% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Venus Remedies | 31.25% | 118.56% | 246.55% | 278.76% | 45.01% | 17.56% |
| Wanbury | 5.29% | 304.80% | 653.92% | 347.79% | 229.78% | 102.70% |
News Based Sentiment: Venus Remedies vs Wanbury
Venus Remedies
News based Sentiment: MIXED
Venus Remedies reported impressive Q1 FY2026 results, driving share price increases and attracting institutional investment. However, analyst forecasts suggest a potential price drop, and the stock is trading at a significant premium to its intrinsic value, creating a mixed investment outlook.
Wanbury
News sentiment data is not available for Wanbury at this time.
Performance & Financial Health Analysis: Venus Remedies vs Wanbury
| Metric | VENUSREM | WANBURY |
|---|---|---|
| Market Information | ||
| Market Cap | ₹6.24B | ₹9.20B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 11,741 | 84,112 |
| 90 Day Avg. Volume | 12,650 | 67,749 |
| Last Close | ₹461.75 | ₹266.25 |
| 52 Week Range | ₹270.25 - ₹567.80 | ₹154.01 - ₹329.70 |
| % from 52W High | -18.68% | -19.24% |
| All-Time High | ₹639.00 (Aug 09, 2021) | ₹329.70 (May 12, 2025) |
| % from All-Time High | -27.74% | -19.24% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.21% | 0.25% |
| Quarterly Earnings Growth | 6.87% | 12.00% |
| Financial Health | ||
| Profit Margin (TTM) | 0.08% | 0.07% |
| Operating Margin (TTM) | 0.03% | 0.13% |
| Return on Equity (TTM) | 0.08% | 0.52% |
| Debt to Equity (MRQ) | 0.30 | 298.48 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹419.65 | ₹18.08 |
| Cash per Share (MRQ) | ₹116.93 | ₹3.96 |
| Operating Cash Flow (TTM) | ₹883.16M | ₹341.38M |
| Levered Free Cash Flow (TTM) | ₹453.15M | ₹305.30M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | ₹0.00 | ₹0.00 |
Valuation & Enterprise Metrics Analysis: Venus Remedies vs Wanbury
| Metric | VENUSREM | WANBURY |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 11.44 | 22.12 |
| Forward P/E | N/A | N/A |
| PEG Ratio | 0.02 | 0.02 |
| Price to Sales (TTM) | 0.92 | 1.45 |
| Price to Book (MRQ) | 1.09 | 15.42 |
| Market Capitalization | ||
| Market Capitalization | ₹6.24B | ₹9.20B |
| Enterprise Value | ₹4.59B | ₹10.77B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 0.68 | 1.71 |
| Enterprise to EBITDA | 6.91 | 11.94 |
| Risk & Other Metrics | ||
| Beta | 0.40 | 0.15 |
| Book Value per Share (MRQ) | ₹419.65 | ₹18.08 |
Financial Statements Comparison: Venus Remedies vs Wanbury
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | VENUSREM | WANBURY |
|---|---|---|
| Revenue/Sales | ₹1.32B | ₹1.72B |
| Cost of Goods Sold | ₹741.50M | ₹843.26M |
| Gross Profit | ₹577.50M | ₹876.73M |
| Research & Development | ₹39.90M | N/A |
| Operating Income (EBIT) | ₹39.20M | ₹262.46M |
| EBITDA | ₹187.90M | ₹314.71M |
| Pre-Tax Income | ₹126.00M | ₹190.54M |
| Income Tax | ₹30.10M | ₹-12.02M |
| Net Income (Profit) | ₹95.90M | ₹202.57M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | VENUSREM | WANBURY |
|---|---|---|
| Cash & Equivalents | ₹575.23M | ₹40.61M |
| Total Current Assets | ₹4.52B | ₹1.93B |
| Total Current Liabilities | ₹1.36B | ₹1.75B |
| Long-Term Debt | ₹0 | ₹1.61B |
| Total Shareholders Equity | ₹5.61B | ₹592.72M |
| Retained Earnings | ₹2.15B | N/A |
| Property, Plant & Equipment | ₹1.07B | ₹2.00B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | VENUSREM | WANBURY |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | VENUSREM | WANBURY |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 11,741 | 84,112 |
| Average Daily Volume (90 Day) | 12,650 | 67,749 |
| Shares Outstanding | 13.37M | 32.77M |
| Float Shares | 6.79M | 14.71M |
| % Held by Insiders | 0.50% | 0.49% |
| % Held by Institutions | 0.01% | 0.04% |
Dividend Analysis & Yield Comparison: Venus Remedies vs Wanbury
| Metric | VENUSREM | WANBURY |
|---|---|---|
| Last 12-Month Dividend | ₹0.00 | ₹0.00 |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | ₹0.00 | ₹0.00 |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | ₹0.00 | ₹0.00 |
| Ex-Dividend Date | N/A | N/A |